StockStory has identified Waters Corporation as the primary healthcare equity for long-term allocation, while classifying Bruker and Bio-Techne as names to avoid. The analysis comes as healthcare stocks have outperformed the broader market, gaining 31.5% over the past six months compared to a 6.8% rise for the S&P 500. The firm argues that while the sector has seen strong recent performance, only a select few companies are positioned to sustain returns amid a new wave of competition driven by venture capital influx.
Waters Corporation, which manufactures analytical instruments for liquid chromatography and mass spectrometry, is the sole stock in the report with a positive outlook. The company, founded in 1958, carries a market capitalization of $44.57 billion. StockStory highlights projected revenue growth of 48.5% for the next 12 months, a figure that exceeds its two-year trend and suggests accelerating demand. The firm also notes a free cash flow margin of 14.9%, which it describes as well above peer levels, providing Waters with the option to reinvest in the business or return capital to investors. At $454.91 per share, Waters trades at a forward P/E of 29.4x.
In contrast, Bruker, a developer of scientific instruments with a market cap of $8.77 billion, is flagged for potential strategic adjustments or reliance on mergers and acquisitions to drive growth. The report points to organic sales performance over the past two years and notes that earnings per share remained flat while revenue grew over the last five years, indicating incremental sales were less profitable. With diminishing returns on capital, Bruker shares at $57.59 imply a forward P/E of 25.6x.
Bio-Techne, which produces specialized biological products for laboratories, faces similar concerns regarding its growth trajectory. The company, with a market cap of $11.38 billion, has shown an absence of organic revenue growth over the past two years, suggesting a need for acquisitions to expand. Its modest revenue base of $1.22 billion is cited as limiting fixed cost leverage compared to larger competitors. Additionally, shrinking returns on capital indicate that previous and ongoing investments have not yielded desired results. Bio-Techne shares at $72.64 trade at a forward P/E of 35.3x.